---
title: "Vericel Corp 2Q 2026: Revenue $77.46M, EPS $0.04— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294369667.md"
description: "Vericel Corp reported Q2 2026 revenue of $77.46M, up 22.5% year-over-year, driven by increased MACI and Epicel volumes and price expansion. Net income turned positive at $2.21M compared to a loss in the prior year, with diluted EPS rising to $0.04 from ($0.01). Key developments include the launch of MACI Arthro, expansion of the surgeon target base, production transition to the Burlington facility, and ongoing clinical trials for MASCOT ankle."
datetime: "2026-07-30T12:51:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294369667.md)
  - [en](https://longbridge.com/en/news/294369667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294369667.md)
---

# Vericel Corp 2Q 2026: Revenue $77.46M, EPS $0.04— 10-Q Summary

Vericel Corp reported second-quarter 2026 results with revenue of $77.46M, up 22.5% from $63.24M a year earlier, and net income of $2.21M versus a loss of $553K in the prior-year quarter; diluted EPS was $0.04 compared with ($0.01) in Q2 2025.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$77.46M

$63.24M

22.5%

Net income²

$2.21M

($553K)

498.9%

Diluted EPS³

$0.04

($0.01)

500%

_¹ Reported as “Total revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Net income (loss) per common share”._

**Business Highlights**

-   Revenue growth was driven by higher MACI and Epicel volume and price expansion.
-   MACI Arthro, launched in Q3 2024, is expanding arthroscopic delivery and associated instrument sales.
-   Surgeon interest and the MACI target base expanded from roughly 5,000 to 7,000 surgeons.
-   Burlington manufacturing facility received approval for MACI production in March 2026 and the company is transitioning production there.
-   Clinical and market expansion initiatives include the MASCOT ankle trial initiated in Q4 2025 and pursuit of UK regulatory approval for MACI.

Original SEC Filing: Vericel Corp \[ VCEL \] - 10-Q - Jul. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [VCEL.US](https://longbridge.com/en/quote/VCEL.US.md)

## Related News & Research

- [Vericel Q2 2026 earnings preview](https://longbridge.com/en/news/294226819.md)
- [Vericel beats Q2 revenue estimates, boosts annual outlook](https://longbridge.com/en/news/294362078.md)
- [Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | VCEL Stock News](https://longbridge.com/en/news/294360787.md)
- [Truist Financial Reaffirms Their Buy Rating on Vericel (VCEL)](https://longbridge.com/en/news/294508492.md)
- [Why GameStop stock just wiped out all its 2026 gains](https://longbridge.com/en/news/294725670.md)